Collections Top Papers for 2020 - Radiatio...

Top Papers for 2020 - Radiation Oncology
David A Palma, Robert Olson, Stephen Harrow, Stewart Gaede, Alexander V Louie, Cornelis Haasbeek, Liam Mulroy, Michael Lock, George B Rodrigues, Brian P Yaremko, Devin Schellenberg, Belal Ahmad, Sashendra Senthi, Anand Swaminath, Neil Kopek, Mitchell Liu, Karen Moore, Suzanne Currie, Roel Schlijper, Glenn S Bauman, Joanna Laba, X Melody Qu, Andrew Warner, Suresh Senan
PURPOSE: The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data that test this paradigm are lacking. METHODS: We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 v 4-5) and randomized in a 1:2 ratio between palliative standard-of-care (SOC) treatments (arm 1) and SOC plus SABR (arm 2)...
September 1, 2020: Journal of Clinical Oncology
Jeevin Shahi, Ian Poon, Yee C Ung, May Tsao, Georg A Bjarnason, Nauman H Malik, Liying Zhang, Alexander V Louie, Patrick Cheung
PURPOSE: Stereotactic body radiation therapy (SBRT) to metastatic mediastinal and hilar lymphadenopathy (MHL) is challenging owing to the proximity of centrally located organs-at-risk. As limited data exist on the safety and efficacy of SBRT for MHL, a retrospective review of clinical outcomes was conducted from a large academic center. METHODS AND MATERIALS: Eligible patients received SBRT to MHL between 2014 to 2019 for the following indications: oligometastases, oligoprogression, or local control of a dominant area of progression...
March 1, 2021: International Journal of Radiation Oncology, Biology, Physics
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, Abdulla Alhasso, David J Bloomfield, Charlie Chan, Mark Churn, Susan Cleator, Charlotte E Coles, Andrew Goodman, Adrian Harnett, Penelope Hopwood, Anna M Kirby, Cliona C Kirwan, Carolyn Morris, Zohal Nabi, Elinor Sawyer, Navita Somaiah, Liba Stones, Isabel Syndikus, Judith M Bliss, John R Yarnold
BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial. METHODS: FAST-Forward is a multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 radiotherapy centres and 50 referring hospitals) in the UK...
May 23, 2020: Lancet
Jennifer Y Wo, Christopher J Anker, Jonathan B Ashman, Nishin A Bhadkamkar, Lisa Bradfield, Daniel T Chang, Jennifer Dorth, Julio Garcia-Aguilar, David Goff, Dustin Jacqmin, Patrick Kelly, Neil B Newman, Jeffrey Olsen, Ann C Raldow, Erika Ruiz-Garcia, Karyn B Stitzenberg, Charles R Thomas, Q Jackie Wu, Prajnan Das
PURPOSE: This guideline reviews the evidence and provides recommendations for the indications and appropriate technique and dose of neoadjuvant radiation therapy (RT) in the treatment of localized rectal cancer. METHODS: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on the use of RT in preoperative management of operable rectal cancer. These questions included the indications for neoadjuvant RT, identification of appropriate neoadjuvant regimens, indications for consideration of a nonoperative or local excision approach after chemoradiation, and appropriate treatment volumes and techniques...
October 20, 2020: Practical Radiation Oncology
Yungan Tao, Anne Auperin, Pierre Blanchard, Marc Alfonsi, Xu-Shan Sun, Michel Rives, Yoann Pointreau, Joël Castelli, Pierre Graff, Stéphanie Wong Hee Kam, Juliette Thariat, Ovidiu Veresezan, Steve Heymann, Sophie Renard-Oldrini, Cédrik Lafond, Alexandre Cornely, Odile Casiraghi, Pierre Boisselier, Michel Lapeyre, Julian Biau, Jean Bourhis
BACKGROUND: Concurrent chemoradiotherapy (CRT) is the standard of care (SoC) in locally advanced (LA) head and neck squamous cell carcinomas (HNSCC). This trial was designed to test whether dose-escalated IMRT and cisplatin could improve locoregional control without increasing complications over 3D-radiotherapy. METHODS: Patients were randomized between 70 Gy/35F in 7 weeks with 3D-RT (Arm A) versus 75 Gy/35F with IMRT (Arm B). Both arms received 50 Gy in 25 fractions followed by a sequential boost of 20 Gy/10F in Arm A and 25 Gy/10F to gross tumor volume in Arm B, as well as 3 cycles of cisplatin at 100 mg/m2 during RT...
September 2020: Radiotherapy and Oncology
Maxime J M van der Valk, Corrie A M Marijnen, Boudewijn van Etten, Esmée A Dijkstra, Denise E Hilling, Elma Meershoek-Klein Kranenbarg, Hein Putter, Annet G H Roodvoets, Renu R Bahadoer, Tone Fokstuen, Albert Jan Ten Tije, Jaume Capdevila, Mathijs P Hendriks, Ibrahim Edhemovic, Andrès M R Cervantes, Derk Jan A de Groot, Per J Nilsson, Bengt Glimelius, Cornelis J H van de Velde, Geke A P Hospers
BACKGROUND: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision is widely accepted as the standard of care for high-risk rectal cancer. Adjuvant chemotherapy is advised in several international guidelines, although the survival benefit remains unclear and compliance is poor. The current multidisciplinary approach has led to major improvements in local control, yet the occurrence of distant metastases has not decreased accordingly. The combination of short-course radiotherapy (SCRT) and chemotherapy in the waiting period before surgery might have several benefits, including higher compliance, downstaging and better effect of systemic therapy...
June 2020: Radiotherapy and Oncology
Timothy Whelan, Mark Levine, Jonathan Sussman
No abstract text is available yet for this article.
October 1, 2020: Journal of Clinical Oncology
Gokoulakrichenane Loganadane, Pauline T Truong, Alphonse G Taghian, Dušanka Tešanović, Mawei Jiang, Fady Geara, Meena S Moran, Yazid Belkacemi
Regional nodal irradiation has gained interest in recent years with the publication of several important randomized trials and the availability of more conformal techniques. Target volume delineation represents a critical step in the radiation planning process. Adequate coverage of the microscopic tumor spread to regional lymph nodes must be weighed against exposure of critical structures such as the heart and lungs. Among available guidelines for delineating the clinical target volume for the breast/chest wall and regional nodes, the Radiation Therapy Oncology Group and European Society for Radiotherapy and Oncology guidelines are the most widely used internationally...
July 1, 2020: International Journal of Radiation Oncology, Biology, Physics
Maria Gebre-Medhin, Eva Brun, Per Engström, Hedda Haugen Cange, Lalle Hammarstedt-Nordenvall, Johan Reizenstein, Jan Nyman, Edvard Abel, Signe Friesland, Helena Sjödin, Henrik Carlsson, Karin Söderkvist, Marcus Thomasson, Björn Zackrisson, Per Nilsson
PURPOSE: We performed an open-label randomized controlled phase III study comparing treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus concomitant cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC; stage III-IV according to the Union for International Cancer Control TNM classification, 7th edition). MATERIALS AND METHODS: Eligible patients were randomly assigned 1:1 to receive either intravenous cetuximab 400 mg/m2 1 week before start of RT followed by 250 mg/m2 /wk, or weekly intravenous cisplatin 40 mg/m2 , during RT...
October 14, 2020: Journal of Clinical Oncology
Philip M Poortmans, Caroline Weltens, Catherine Fortpied, Carine Kirkove, Karine Peignaux-Casasnovas, Volker Budach, Femke van der Leij, Ernest Vonk, Nicola Weidner, Sofia Rivera, Geertjan van Tienhoven, Alain Fourquet, Georges Noel, Mariacarla Valli, Matthias Guckenberger, Eveline Koiter, Severine Racadot, Roxolyana Abdah-Bortnyak, Erik F Van Limbergen, Antoine Engelen, Peter De Brouwer, Henk Struikmans, Harry Bartelink
BACKGROUND: 10-year results from several studies showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery in patients with breast cancer. We present the scheduled 15-year analysis of the European Organisation for Research and Treatment of Cancer (EORTC) 22922/10925 trial, which aims to investigate the impact on overall survival of elective internal mammary and medial supraclavicular (IM-MS) irradiation...
December 2020: Lancet Oncology
Paul D Brown, Vinai Gondi, Stephanie Pugh, Wolfgang A Tome, Jeffrey S Wefel, Terri S Armstrong, Joseph A Bovi, Cliff Robinson, Andre Konski, Deepak Khuntia, David Grosshans, Tammie L S Benzinger, Deborah Bruner, Mark R Gilbert, David Roberge, Vijayananda Kundapur, Kiran Devisetty, Sunjay Shah, Kenneth Usuki, Bethany Marie Anderson, Baldassarre Stea, Harold Yoon, Jing Li, Nadia N Laack, Tim J Kruser, Steven J Chmura, Wenyin Shi, Snehal Deshmukh, Minesh P Mehta, Lisa A Kachnic
PURPOSE: Radiation dose to the neuroregenerative zone of the hippocampus has been found to be associated with cognitive toxicity. Hippocampal avoidance (HA) using intensity-modulated radiotherapy during whole-brain radiotherapy (WBRT) is hypothesized to preserve cognition. METHODS: This phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine. The primary end point was time to cognitive function failure, defined as decline using the reliable change index on at least one of the cognitive tests...
April 1, 2020: Journal of Clinical Oncology
Joanna Socha, Laura Kairevice, Lucyna Kępka, Wojciech Michalski, Mateusz Spałek, Karol Paciorek, Krzysztof Bujko
PURPOSE: National Comprehensive Cancer Network guidelines recommend either long-course chemoradiation (LC) or short-course radiation (SC, 5 × 5 Gy) for rectal cancer before total mesorectal excision. However, they do not recommend SC for low-lying tumors. As early toxicity of SC is lower than that of LC, and postoperative complications as well as late toxicity are similar, the probable reason is a notion that for low-lying tumors LC may be more effective than SC in assuring local control...
December 1, 2020: International Journal of Radiation Oncology, Biology, Physics
Csaba Polgár, Tibor Major, Zoltán Takácsi-Nagy, János Fodor
PURPOSE: To report the 20-year results of a phase 3 clinical trial comparing the survival and cosmetic results of breast-conserving surgery followed by partial breast irradiation (PBI) or whole breast irradiation (WBI). METHODS AND MATERIALS: Between 1998 and 2004, 258 selected patients with low-risk invasive breast carcinoma (pT1 pN0-1mi, grade 1-2, nonlobular breast cancer) resected with negative margins were randomized after breast-conserving surgery to receive PBI (n = 128) or 50 Gy WBI (n = 130)...
March 15, 2021: International Journal of Radiation Oncology, Biology, Physics
Adrienne Boire, Priscilla K Brastianos, Livia Garzia, Manuel Valiente
Brain metastasis, which commonly arises in patients with lung cancer, breast cancer and melanoma, is associated with poor survival outcomes and poses distinct clinical challenges. The brain microenvironment, with its unique cell types, anatomical structures, metabolic constraints and immune environment, differs drastically from microenvironments of extracranial lesions, imposing a distinct and profound selective pressure on tumour cells that, in turn, shapes the metastatic process and therapeutic responses...
January 2020: Nature Reviews. Cancer
Robert T Dess
No abstract text is available yet for this article.
March 15, 2020: International Journal of Radiation Oncology, Biology, Physics
Lei Liu, Yongqiang Yang, Qi Guo, Bixin Ren, Qiliang Peng, Li Zou, Yaqun Zhu, Ye Tian
PURPOSE: To compare the efficacy and toxicity of hypofractionated radiotherapy versus conventional fractionated radiotherapy in postmastectomy breast cancer using meta-analysis. METHODS: The PubMed, EMbase, Cochrane Library, Google Scholar, Wan Fang and CNKI databases were searched to identify controlled clinical trials comparing hypofractionated radiotherapy versus conventional fractionated radiotherapy in postmastectomy breast cancer. Overall survival (OS) was the primary endpoint, and disease-free survival (DFS), locoregional recurrence (LRR), distant metastasis (DM), acute skin toxicity, acute lung toxicity, late skin toxicity, lymphedema,, shoulder restriction, and late cardiac related toxicity were the secondary endpoints...
January 17, 2020: Radiation Oncology
Michael J Moravan, Peter E Fecci, Carey K Anders, Jeffrey M Clarke, April K S Salama, Justus D Adamson, Scott R Floyd, Jordan A Torok, Joseph K Salama, John H Sampson, Paul W Sperduto, John P Kirkpatrick
Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of patients with late-stage cancer and traditionally are associated with a poor prognosis. The management of patients with BM has become increasingly complex because of new and emerging systemic therapies and advancements in radiation oncology and neurosurgery. Current therapies include stereotactic radiosurgery, whole-brain radiation therapy, surgical resection, laser-interstitial thermal therapy, systemic cytotoxic chemotherapy, targeted agents, and immune-checkpoint inhibitors...
April 1, 2020: Cancer
Vedang Murthy, Priyamvada Maitre, Jatin Bhatia, Sadhana Kannan, Rahul Krishnatry, Gagan Prakash, Ganesh Bakshi, Mahendra Pal, Santosh Menon, Umesh Mahantshetty
AIM: To report toxicity and quality of life (QOL) outcomes from a randomised trial of prostate only versus whole pelvic radiotherapy in high risk, node negative prostate cancer. MATERIALS/METHODS: Patients with localised prostate adenocarcinoma and nodal involvement risk > 20%, were randomised to prostate only (PORT, 68 Gy/25# to prostate) and whole pelvis (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis) arms with stratification for TURP, Gleason score, baseline PSA, and type of androgen deprivation therapy (ADT)...
April 2020: Radiotherapy and Oncology
Paul M Putora, Dirk De Ruysscher, Markus Glatzer, Joachim Widder, Paul Van Houtte, Esther G C Troost, Ben J Slotman, Sara Ramella, Christoph Pöttgen, Stephanie Peeters, Ursula Nestle, Fiona McDonald, Cecile Le Pechoux, Rafal Dziadziuszko, José Belderbos, Corinne Faivre-Finn
BACKGROUND: The role of prophylactic cranial irradiation (PCI) and thoracic radiotherapy (TRT) is unclear in resected small cell lung cancer (SCLC). METHODS: Thirteen European radiotherapy experts on SCLC were asked to describe their strategies on PCI and TRT for patients with resected SCLC. The treatment strategies were converted into decision trees and analyzed for consensus and discrepancies. RESULTS: For patients with resected SCLC and positive lymph nodes most experts recommend prophylactic cranial irradiation and thoracic radiotherapy...
April 2020: Radiotherapy and Oncology
Vérane Achard, Pelagia Tsoutsou, Thomas Zilli
No abstract text is available yet for this article.
July 1, 2020: International Journal of Radiation Oncology, Biology, Physics
2020-12-17 20:50:33
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"